Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways

Biochemical Pharmacology

Volumn 58, Issue 5, 1999, Pages 787-796

  Bort, Roque ^a,b   MacÉ, Katherine ^c   Boobis, Alan ^d   Gómez Lechón, María José ^a   Pfeifer, Andrea ^c   Castell, José ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

CYP2C; Cytochrome P450; Diclofenac; In vitro metabolism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DICLOFENAC; DRUG METABOLITE;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; HUMANS; MICROSOMES, LIVER; OXIDATION-REDUCTION; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0032797632     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00167-7     Document Type: Article

References (30)

1. Scully L.J., Clarke D., Barr R.J. Diclofenac-induced hepatitis Three cases with features of autoimmune chronic active hepatitis . Dig Dis Sci. 38:1993;744-751.
2. Stierlin H., Faigle J.W., Sallman A., Küng W., Richter W.J., Kriemler H.P., Alt K.O., Winkler T. Biotransformation of diclofenac sodium (Voltaren) in animals and man. I. Isolation and identification of principal metabolites. Xenobiotica. 9:1979;601-610.
3. Riess W., Stierlin H., Degen P., Faigle J.W., Gérardin A., Moppert J., Sallmann A., Schmid K., Schweizer A., Sulc M., Theobald W., Wagner J. Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren. Scand J Rheumatol Suppl. 22:1978;17-29.
4. Faigle J.W., Böttcher I., Godbillon J., Kriemler H.P., Schlumpf E., Schneider W., Schweizer A., Stierlin H., Winkler T. A new metabolite of diclofenac sodium in human plasma. Xenobiotica. 18:1988;1191-1197.
5. Helfgott S.M., Sandberg-Cook J., Zakim D., Nestler J. Diclofenac-associated hepatotoxicity. JAMA. 264:1990;2660-2662.
6. Sallie R. Diclofenac hepatitis. J Hepatol. 11:1990;281.
7. Ouellette G.S., Slitzky B.E., Gates J.A., Lagarde S., West A.B. Reversible hepatitis associated with diclofenac. J Clin Gastroenterol. 13:1991;205-210.
8. Purcell P., Henry D., Melville G. Diclofenac hepatitis. Gut. 32:1991;1381-1385.
9. Iveson T.J., Ryley N.G., Kelly P.M., Trowell J.M., McGee J.O., Chapman R.W.G. Diclofenac associated hepatitis. J Hepatol. 10:1990;85-89.
10. Gil M.L., Ramirez M.C., Terencio M.C., Castell J.V. Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac. Biochim Biophys Acta. 1272:1995;140-144.
11. Miyamoto G., Zahid N., Uetrecht J.P. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem Res Toxicol. 10:1997;414-419.
12. Pohl LR, Studies of the metabolic basis of hepatotoxicity caused by the nonsteroidal antiinflammatory drug diclofenac. In: Mecanism of Toxicity and Cell Death Manifested by Substrates of Drug Metabolizing Enzymes, Proceedings of the XIth International Symposium on Microsomes and Drug Oxidations, Los Angeles, U.S.A., 21-24 July 1996 (Eds KREBS Convention Management Services), p. 68.
13. Leemann T., Transon C., Dayer P. Cytochrome P450TB (CYP2C) A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver . Life Sci. 52:1993;29-34.
14. Transon C., Lecoeur S., Leemann T., Beaune P., Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol. 51:1996;79-85.
15. Bort R., Ponsoda X., Jover R., Gómez-Lechón M.J., Castell J.V. Diclofenac toxicity to hepatocytes A role for drug metabolism in cell toxicity . J Pharm Exp Ther. 288:1999;65-72.
16. Bort R., Ponsoda X., Carrasco E., Gómez-Lechón M.J., Castell J.V. Metabolism of aceclofenac in humans. Drug Metab Dispos. 24:1996;834-841.
17. Gómez-Lechón M.J., López P., Donato T., Montoya A., Larrauri A., Giménez P., Trullenque R., Fabra R., Castell J.V. Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo. In Vitro Cell Dev Biol. 26:1990;67-74.
18. Pfeifer A.M.A., Cole K.E., Smoot D.T., Weston A., Groopman J.D., Shields P.G., Vignaud J.-M., Juillerat M., Lipsky M.M., Trump B., Lechner J.F., Harris C.C. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci USA. 90:1993;5123-5127.
19. Macé K., Aguilar F., Wang J.S., Gómez-Lechón M.J., Gonzalez F.J., Groopman J., Harris C.C., Pfeifer A.M.A. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis. 18:1997;1291-1297.
20. Bort R, Macé K, Gómez-Lechón MJ, Pfeifer A and Casteu JV, High expression of human CYP2C in immortalised human liver epithelial cells. Toxicol In Vitro (in press), 1999.
21. Boobis A.R., Brodie M.J., Kahn G.C., Fletcher D.R., Saunders J.H., Davies D.S. Monooxigenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol. 9:1980;11-19.
22. Sesardic D., Boobis A.R., Murray S., Segura J., De la Torre R., Davies D.S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmac. 29:1990;651-663.
23. Raunio H., Syngelmä T., Pasanen M., Juvonen R., Honkakoski P., Kairaluoma M.A., Sotaniemi E.A., Lang M.A., Pelkonen O. Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem Pharmacol. 37:1988;3889-3895.
24. Mancy A., Dijols S., Poli S., Guengerich P., Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9 . Biochemistry. 35:1996;16205-16212.
25. Inaba T., Jurima M., Mahon W.A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450 Mephenytoin p-hydroxylase and sparteine monooxygenase . Drug Metab Dispos. 13:1985;443-448.
26. Peter R., Böcker R.G., Beaune P.H., Iwasaki N., Guengerich F.P., Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem Res Toxicol. 3:1990;566-573.
27. Chang T.K.H., Gonzalez F.J., Waxman D.J. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Byophys. 311:1994;437-442.
28. Hasan M.M., Najib N.M., Muti H. A comparative bioavailability study on two sustained-release formulations of diclofenac sodium following a single dose administration. Int J Clin Pharmacol Ther Toxicol. 31:1993;387-391.
29. Relling M.V., Aoyama T., Gonzalez F.J., Meyer U.A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther. 252:1990;442-447.
30. Remmel R.P., Burchell B. Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol. 46:1993;559-566.